Profile data is unavailable for this security.
About the company
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
- Revenue in EUR (TTM)30.06m
- Net income in EUR-39.70m
- Incorporated2003
- Employees102.00
- LocationNanobiotix SA60 rue de WattigniesPARIS 75012FranceFRA
- Phone+33 140260470
- Fax+33 140260444
- Websitehttps://www.nanobiotix.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eurofins-Cerep SA | 44.07m | 7.64m | 107.94m | 228.00 | 14.13 | 1.67 | 11.23 | 2.45 | 1,514.43 | 1,514.43 | 8,743.94 | 12,820.37 | 0.5864 | 1.67 | 5.08 | 193,287.10 | 10.16 | 14.21 | 12.22 | 17.51 | 85.01 | 73.61 | 17.33 | 19.77 | 4.87 | -- | 0.00005 | -- | -7.47 | 11.60 | -33.72 | 14.64 | -- | -- |
| Inventiva SA | 17.48m | -110.43m | 108.37m | 112.00 | -- | -- | -- | 6.20 | -2.45 | -2.45 | 0.3854 | -0.6146 | 0.1884 | -- | 9.18 | 156,044.60 | -116.84 | -54.30 | -207.08 | -69.98 | -- | -- | -620.31 | -669.97 | 0.9524 | -19.98 | 6.96 | -- | 43.50 | 40.46 | -103.46 | -- | -0.33 | -- |
| Transgene SA | 7.63m | -22.33m | 137.32m | 158.00 | -- | 6.69 | -- | 17.99 | -0.2227 | -0.2227 | 0.0759 | 0.1553 | 0.1368 | -- | 4.28 | 48,316.46 | -40.00 | -24.81 | -50.27 | -29.79 | -- | -- | -292.48 | -193.24 | -- | -- | 0.4764 | -- | -23.68 | 1.51 | 31.94 | -- | 14.44 | -- |
| Cellectis SA | 17.67m | -88.85m | 150.68m | 235.00 | -- | 1.12 | -- | 8.53 | -1.40 | -1.12 | 0.2356 | 1.86 | 0.0619 | -- | 3.86 | 75,185.34 | -31.74 | -24.08 | -46.51 | -30.69 | -- | -64.64 | -513.02 | -308.24 | -- | -6.95 | 0.4142 | -- | -64.26 | -15.57 | -20.55 | -- | -26.15 | -- |
| Ose Immunotherapeutics SA | 2.23m | -23.00m | 157.96m | 55.00 | -- | 6.80 | -- | 70.93 | -1.18 | -1.18 | 0.1138 | 1.06 | 0.0256 | -- | 3.22 | 40,490.91 | -26.46 | -17.17 | -33.15 | -20.55 | -- | -- | -1,032.87 | -94.71 | -- | -55.59 | 0.6659 | -- | -87.83 | -38.07 | -29.52 | -- | -17.11 | -- |
| Innate Pharma SA | 24.85m | -34.05m | 163.96m | 168.00 | -- | 5.69 | -- | 6.60 | -0.4215 | -0.4215 | 0.3078 | 0.3557 | 0.1418 | -- | 14.93 | 138,826.80 | -19.43 | -8.83 | -24.80 | -12.11 | 88.00 | 93.17 | -137.03 | -55.55 | -- | -- | 0.7527 | -- | 4.68 | -8.27 | 86.94 | -- | 10.50 | -- |
| Genfit SA | 38.18m | -28.89m | 194.01m | 159.00 | -- | 2.85 | -- | 5.08 | -0.5814 | -0.5814 | 0.7681 | 1.36 | 0.1961 | 542.00 | 3.52 | 240,100.60 | -14.84 | -12.57 | -18.55 | -15.30 | 94.32 | 94.96 | -75.69 | -76.23 | 2.94 | -7.78 | 0.5080 | -- | 43.70 | 38.49 | -21.82 | -- | -3.27 | -- |
| Nanobiotix SA | 30.06m | -39.70m | 210.69m | 102.00 | -- | -- | -- | 7.01 | -1.10 | -1.10 | 0.814 | -0.0391 | 0.3912 | -- | 19.59 | 294,686.30 | -51.67 | -54.11 | -120.56 | -80.68 | -- | -- | -132.08 | -756.15 | -- | -1.98 | 1.04 | -- | -- | 203.88 | 30.40 | -- | -7.81 | -- |
| Eurobio Scientific SA | 130.00m | 4.84m | 254.68m | 137.00 | 57.60 | 1.55 | 14.16 | 1.96 | 0.4315 | 0.4315 | 11.59 | 16.02 | 0.4018 | 3.19 | 4.31 | 948,927.00 | 1.49 | 16.91 | 1.80 | 21.53 | 47.11 | 50.95 | 3.72 | 23.34 | 2.32 | 4.03 | 0.3666 | 0.00 | -14.81 | 20.80 | -80.61 | -- | 20.02 | -- |
| Sensorion SA | 0.00 | -22.06m | 285.48m | 50.00 | -- | 5.34 | -- | -- | -0.2063 | -0.2063 | 0.00 | 0.1779 | 0.00 | -- | -- | -- | -51.64 | -35.12 | -71.66 | -46.97 | -- | -- | -- | -- | -- | -- | 0.0794 | -- | -- | -- | 4.94 | -- | 126.45 | -- |
Data as of Sep 18 2024. Currency figures normalised to Nanobiotix SA's reporting currency: Euro EUR
10.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invus Public Equities Advisors LLCas of 24 Apr 2024 | 3.07m | 6.51% |
| Baillie Gifford & Co.as of 07 Sep 2023 | 488.43k | 1.04% |
| Medical Strategy GmbHas of 31 May 2024 | 448.09k | 0.95% |
| Financi�re Arbevel SAas of 30 Dec 2022 | 168.19k | 0.36% |
| Generali Asset Management SGR SpAas of 28 Feb 2022 | 153.00k | 0.33% |
| SG 29 Haussmann SASUas of 11 Sep 2024 | 110.00k | 0.23% |
| OFI Invest Asset Management SAas of 29 Aug 2024 | 88.33k | 0.19% |
| SSgA Funds Management, Inc.as of 05 Sep 2024 | 87.58k | 0.19% |
| Talence Gestion SASas of 30 Aug 2024 | 77.00k | 0.16% |
| BG Fund Management Luxembourg SAas of 31 Dec 2023 | 50.49k | 0.11% |
More ▼
Data from 31 May 2024 - 12 Sep 2024Source: FactSet Research Systems Inc.
